Bioactive compounds and alleviation of symptoms of bowel inflammation
Bioactive Molecules and Pharmaceuticals · 01.05.2026 · 3 (4) · 34-53
DOI: 10.31989/bmp.v3i4.1980 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioactive Molecules and Pharmaceuticals, online erschienen am 01.05.2026. Verfasst von Jonathan Wright und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Inflammatory bowel disease (IBD) imposes a significant and growing global health burden, and current therapeutic options remain substantially limited. This mini-review evaluates the mechanistic basis and clinical evidence for four major dietary bioactive compound sources (sulforaphane from cruciferous vegetables, curcumin from turmeric, omega-3 fatty acids, and polyphenols) as complementary interventions for bowel inflammation. These bioactive compound classes converge on key anti-inflammatory pathways, including nuclear factor erythroid 2-related factor 2 (Nrf2) activation, nuclear factor kappa B (NF-κB) suppression, intestinal barrier enhancement, and gut microbiome modulation. The clinical evidence is strongest for curcumin, a polyphenolic curcuminoid, with systematic reviews of randomized controlled trials demonstrating adjunctive benefit in ulcerative colitis remission maintenance. Sulforaphane, an isothiocyanate, shows robust preclinical efficacy through Nrf2-dependent mechanisms with emerging human evidence. Long-chain omega-3 polyunsaturated fatty acids and plant-derived polyphenols demonstrate strong mechanistic plausibility, although clinical outcomes remain variable. This review positions these classes of dietary bioactive compounds as evidence-based complementary functional food interventions within integrative IBD management frameworks. Novelty: This mini-review uniquely integrates multiple classes of dietary bioactive compounds—specifically isothiocyanates, polyphenolic curcuminoids, omega-3 polyunsaturated fatty acids, and plant-derived polyphenols—into a unified mechanistic framework centered on convergent anti-inflammatory signaling pathways in IBD. Unlike prior reviews that evaluate these bioactive compound classes in isolation, this work comparatively analyzes their shared and distinct roles in modulating Nrf2, NF-κB, gut barrier integrity, and the intestinal microbiome. Additionally, it emphasizes the translational potential of these defined bioactive compound classes within functional food-based therapeutic strategies, bridging mechanistic insights with clinical applicability. Keywords: Inflammatory bowel disease; sulforaphane; dietary bioactive compounds; isothiocyanates; polyphenolic curcuminoids; curcumin; omega-3 polyunsaturated fatty acids; plant-derived polyphenols; gut microbiome; functional foods
Zitieren
APA
Wright, J., Srisukthaveerat, V., Martirosyan, D. M., & Chaiyasit, K. (2026). Bioactive compounds and alleviation of symptoms of bowel inflammation. Bioactive Molecules and Pharmaceuticals, 3(4), 34-53. https://doi.org/10.31989/bmp.v3i4.1980
Vancouver
Wright J, Srisukthaveerat V, Martirosyan DM, Chaiyasit K. Bioactive compounds and alleviation of symptoms of bowel inflammation. Bioactive Molecules and Pharmaceuticals. 2026;3(4):34-53. doi:10.31989/bmp.v3i4.1980
BibTeX
@article{Wright2026,
author = {Wright, Jonathan and Srisukthaveerat, Varit and Martirosyan, Danik Martirosyan and Chaiyasit, Kamon},
title = {Bioactive compounds and alleviation of symptoms of bowel inflammation},
journal = {Bioactive Molecules and Pharmaceuticals},
year = {2026},
volume = {3},
number = {4},
pages = {34--53},
doi = {10.31989/bmp.v3i4.1980}
}
EUVIMED